The BCR gene contributes to Philadelphia-positive leukemogenesis via a number of discrete mechanisms, one of which may be through interaction of its normal gene product with the Bcr/Abl oncoprotein. In the current study this hypothesis was tested in vivo by introducing a Bcr/Abl P190 transgene into mice lacking endogenous bcr protein. Our ®nding, that the P190 BCR/ABL oncogene is still capable of producing leukemia in these mice with indistinguishable latency and clinical pattern as in genetically matched counterparts, rules out any signi®cant or major contribution of the bcr protein as a whole to leukemia development in these mice.
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The BCR gene product has been implicated in regulation of the Rho family of small GTP-binding proteins Rho, Rac and Cdc42 through its exon 3 ± 10 encoded GDP/GTP exchange factor (GEF) domain (Eva and Aaronson, 1985; Hart et al., 1991; Chuang et al., 1995) and its C-terminal GTPase activating protein (GAP) activity (Diekmann et al., 1991; Hart et al., 1992) . BcrGAP activity toward Rac and CDC42 is currently the only well-understood biochemical property of p160
Bcr
. By means of gene knock-out technology, p160
Bcr was found indispensable in vivo for regulation of respiratory burst activity in neutrophils through control of the cellular Rac-GTP/Rac-GDP pool during priming and activation (Voncken et al., 1995a) . The Bcr protein also harbors a novel serine/threonine kinase activity (Stam et al., 1987; Li et al., 1989; Maru and Witte 1991) . BCR exon 1 sequences that encode this catalytic activity are unique in the mammalian genome. Finally, Bcr carries several domains, including a peptide sequence bearing some homology to pleckstrin which potentially direct subcellular localization and interaction with other cellular proteins. The biological signi®cance of these domains and of the serine/threonine kinase domain in vivo is as of yet unclear.
BCR was ®rst identi®ed as a gene encompassing the breakpoint cluster region, a region on human chromosome 22 which undergoes a reciprocal translocation with chromosome 9 in Philadelphia (Ph)-positive leukemia (de Klein et al., 1982) . This [t(9;22)(q34;q11)] translocation fuses BCR gene sequences to the ABL proto-oncogene. Depending on where in the BCR locus the breakpoint occurs, a P190 or a P210 kDa chimeric Bcr/Abl oncoprotein is produced. At the molecular level, the BCR gene contributes to leukemogenesis through a number of discrete mechanisms. Firstly, the BCR promoter controls expression of both the remaining nonrearranged BCR allele and the BCR/ABL oncogene in human leukemia. The observation that the physiological eects of bcr gene ablation in mice are found in those cell types also involved in Ph-positive leukemia in man (Voncken et al., 1995a) most likely pertains to dierential transcriptional regulation of the BCR gene in cells that have respiratory burst activity (granulocytes, macrophages and B-cells).
Secondly, N-terminal Bcr sequences are directly responsible for the activation of the Abl tyrosine kinase in the chimeric Bcr/Abl gene products (Muller et al., 1991; Wang, 1993, 1997) . Thus, through its fusion to Abl, Bcr also contributes at a biochemical level to neoplastic transformation of white blood cells. Finally, Bcr is able to form homotetramers through an N-terminal oligomerization domain constituted by amino acids 28 ± 68 . Because both P210 and P190 Bcr/Abl proteins retain this moiety, Bcr-Bcr/ Abl heteromerization will occur in cells expressing both proteins. Indeed, Bcr consistently co-precipitates with Bcr/Abl from Ph-positive cell lines and is a target for the Bcr/Abl tyrosine kinase Lu et al., 1993; Pendergast et al., 1993; Puil et al., 1994) . Phosphorylation of tyrosine residues in the normal Bcr protein by Bcr/Abl inhibits the Bcr serine/ threonine kinase encoded by BCR exon 1 and conversely, a serine-phosphorylated Bcr peptide from exon 1 inhibits the Bcr/Abl tyrosine kinase activity (Liu et al., 1996a,b) .
We have previously generated mice transgenic for BCR/ABL P190 and P210 which develop leukemia/ lymphoma (Heisterkamp et al., 1990; Voncken et al., 1992 Voncken et al., , 1995b . In a separate study, we have eliminated the cellular bcr function in mice through gene targeting (Voncken et al., 1995a) . The availability of both mouse models for Philadelphia-positive leukemia and a bcr mutant lacking bcr protein allowed us to test the hypothesis that the Bcr protein as a whole contributes to leukemia through its interaction with Bcr/Abl.
Leukemogenesis in the BCR/ABL P190 transgenic mice is usually accompanied by the development of lymphomas which largely consist of malignant lymphoblasts. The bcr protein is expressed in most normal tissues but the highest expression levels are Correspondence: N Heisterkampfound in brain (Figure 1, lane 4) . In the lymphomas, the endogenous p160
bcr is expressed at a very high level, which is comparable to that in brain (Figure 1 compare lanes 1 ± 3 with lane 4) and exceeds that found in bone marrow of disease-free animals (not shown). The bcr protein detected in these lymphoblasts migrates as a double band (Figure 1 ). Fibroblasts transfected with Bcr/Abl but not non-transfected controls also show a double band of endogenous bcr protein (not shown). This indicates that, similar to the CML cell lines, the endogenous bcr interacts with the Bcr/Abl protein and becomes tyrosine phosphorylated in our transgenic mouse model (Liu et al., 1996a) .
In earlier investigations, the development of leukemia was studied in the P190 BCR/ABL transgenic mouse line 623, which was of a B 6 CBA genetic background (Voncken et al., 1992) . Transgenic 623 ospring died reproducibly of pre-B cell acute lymphoblastic leukemia (ALL) or lymphoblastic leukemia lymphoma; 50% mortality was approximately at 10 weeks. The bcr(7/7) genotype was established in an 129Sv background. Introduction of 129Sv chromosomes into the B 6 CBA P190 transgenic background resulted in a signi®cantly increased latency of BCR/ABL-mediated leukemia development both in female and male wild types (Figure 2 , compare open diamonds with small dots).
There was no signi®cant dierence in tumor incidence, nor latency to development of leukemia between genetically matched BCR/ABL-bcr(+/+), BCR/ABL-bcr(7/7) and BCR/ABL-bcr(+/7) animals of either sex. Fifty percent mortality for all 129Sv-background' transgenic female genotypes was about 22 weeks ( Figure 2a ) whereas for males this was at more than 1 year (Figure 2b ). The dierence between males and females may be caused by possible hormone-responsive elements in the transgenic P190 construct, e.g., in the MT promoter segment.
Gross examination of terminally ill animals revealed comparable pathology, independent of the genetic status of the bcr locus. The type of neoplasia that developed was uniform, regardless of genotype: typically, either ALL (high peripheral white blood cell count, splenomegaly, limited lymph node and bone marrow involvement, hind limb paralysis) or lymphoblastic leukemia/lymphoma (splenomegaly, bone marrow involvement and asymmetric lymph node swelling, paralysis) developed. Soft tissue invasion was comparable in BCR/ABL-bcr(7/7) and in (+/+) animals. We also introduced a BCR/ABL P210 transgene (1994-line; Voncken et al., 1995) into the bcr(7/7) background and obtained leukemic animals, indicating that the P210 protein does not require the presence of endogenous bcr protein for leukemogenesis (not shown).
Our ®nding, that the P190 BCR/ABL oncogene is still capable of producing leukemia in transgenic mice when bred into the bcr(7/7) background, with indistinguishable latency and clinical pattern as in genetically matched (+/+) P190 BCR/ABL counterparts, rules out any signi®cant or major contribution of the bcr protein as a whole to the oncogenic process. It remains formally possible that some of the enzymatic activity exhibited by the endogenous bcr protein is 1 2 3 4 Figure 1 Western blot analysis of p160 bcr in lymphomas of BCR/ ABL P190 transgenic mice. Lanes 1 ± 3 contain lysates from three dierent terminally ill animals, lane 4 a brain lysate from a disease-free wild type animal. The arrows point to the bcr doublets in the lymphomas and to the single bcr band in brain. 20 mg of total cellular protein was loaded per lane. Bcr protein was detected with monoclonal antibody AB-2 (Oncogene Science, Inc., NY) which does not react with Bcr/Abl P190 a b Figure 2 Survival curves of BCR/ABL P190 transgenics. The BCR/ABL transgenes were bred into the bcr(7/7) background by mating double transgenic (TG) males of a B 6 CBA background to bcr(7/7) females of a hybrid B 6 CBA/129Sv background. Heterozygous bcr(+/7) transgenic animals were subsequently bred to each other to obtain, with exception of the bcr null mutation, genetically matched wild type/TG and null mutant/TG animals. down-regulated in vivo through tyrosine-phosphorylation by Bcr/Abl. However, only up to 50% (see Figure   1 ) of the endogenous bcr protein appears to be phosphorylated by Bcr/Abl in the P190 bcr(+/+) mice and the remaining 50% would be still active.
The biological signi®cance of the intrinsic serine/ threonine kinase activity of Bcr is unknown since the bcr null mutant has no phenotypic or other evident abnormalities which are easily associated with lack of this activity. However, the GTPase activating protein (GAP) activity of Bcr does have a clear biological function (Voncken et al., 1995) and its substrates, members of the Rho family of GTPases, are implicated in cell proliferation and tumorigenesis (Olson et al., 1995; Qui et al., 1995; Khosravi-Far et al., 1995) .
To investigate the possible eect of tyrosine phosphorylation of Bcr by Bcr/Abl on the bcrGAP activity, both proteins were individually expressed in insect cells and isolated. Bcr protein was subsequently tyrosine-phosphorylated by Bcr/Abl. When phosphorylated and non-phosphorylated Bcr were compared for their ability to stimulate the GTPase activity of Rac1, no dierences were observed (Figure 3 ). Therefore these results do not support the hypothesis that tyrosine-phosphorylation of Bcr eects one of its major biological functions.
Within the context of the Bcr/Abl protein, the size and primary sequence of the Bcr moiety was shown to be important for the generation of leukemia. The results presented in this study limit the contribution of Bcr in Ph-positive leukemia, since we found no evidence to support the hypothesis that the endogenous normal cellular Bcr protein as a whole has an eect on the process of leukemogenesis caused by Bcr/Abl. Figure 3 Comparison of GAP activity of phosphorylated and non-phosphorylated Bcr. GTP-loaded GST-Rac1 was incubated in the presence of phosphorylated GST-Bcr (squares), nonphosphorylated GST-Bcr (circles) and in the absence of GSTBcr (triangles). GST-Rac1, GST-Bcr and GST-Bcr/Abl P210 produced in Sf9 cells were puri®ed as described (Haataja et al., 1997) . GST-Bcr (500 ng) was tyrosine phosphorylated by 100 ng of GST-Bcr/Abl fusion protein in 20 mM PIPES buer, pH 7.0, containing 20 mM MnCl 2 and 1 mM ATP. Ecient transphosphorylation of Bcr by Bcr/Abl was veri®ed by kinase assay as described (Li et al., 1988) . GAP activity was determined by measuring GTP hydrolysis as described (Chuang et al., 1995) . Brie¯y, Rac1 was loaded with [g-32 P]GTP by incubation of the GST-Rac1 fusion protein in 25 mM Tris-HCl, pH 7.5, 4.7 mM EDTA, 1 mM DTT, 0.1 mM MgCl 2 0.1mg/ml bovine serum albumin, 20 mM unlabeled GTP and 10 mCi [g-32 P]GTP (5000 Ci/ mmol, Amersham) at 308C for 4 min. Equally loaded aliquots (as measured by c.p.m. bound) of Rac were used for GAP assays. Hydrolysis was initiated by addition of 50 ng of either nonphosphorylated or tyrosine-phosphorylated GST-Bcr and MgCl 2 and GTP to ®nal concentrations of 17 mM and 170 mM, respectively. The [g-32 P]GTP bound to Rac1 was determined by ®ltration analysis (Chuang et al., 1995) 
